Cowboys owner Jerry Jones said he survived a stage 4 cancer battle that lasted more than a decade
Jones told the Dallas Morning News that he beat stage 4 melanoma. The Cowboys owner's battle lasted more than a decade, he said, and included four surgeries.
"I now have no tumors," Jones, who is 82 years old, told the Dallas Morning News.
Jones told the Dallas Morning News the initial diagnosis came in 2010. Over the next 10 years he had four surgeries, two on his lungs and two on his lymph nodes. He credited the experimental drug PD-1 — short for Programmed Cell Death Protein 1 — for his recovery.
'I was saved by a fabulous treatment and great doctors and a real miracle [drug] called PD-1 [therapy],' Jones said, via the Morning News. 'I went into trials for that PD-1 and it has been one of the great medicines."
In an episode of the soon to be released Netflix series "America's Team: The Gambler and His Cowboys," Jones mentioned having cancer treatments, leading the Dallas Morning News to ask him about it in an interview.
Jones is the NFL's most visible owner, and his Cowboys are the most valuable sports franchise in the world. They're the first sports team to pass the $10 billion mark in Forbes' annual survey. In 2017 — when, according to Jones, he was still fighting stage 4 cancer — he was inducted into the Pro Football Hall of Fame.
Jones has no problem seeking out the media for attention on practically any matters regarding his team. But his long battle against cancer was out of the spotlight, until now.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Is Packers QB Jordan Love in danger of missing Week 2 game vs. Commanders?
Could the Washington Commanders be facing a backup quarterback for their Week 2 showdown against the Green Bay Packers? In Green Bay's preseason opener against the New York Jets, quarterback Jordan Love tried to escape the pocket, and his left hand made contact with a New York defender's helmet, leading to a "ligament issue," per Packers general manager Brian Gutekunst. Love did undergo a procedure, and Gutekunst believes not only will Love be ready for Green Bay's Week 1 contest against the defending NFC North champion Detroit Lions, but that he'd return to practice next week. "Obviously, you guys saw him out there, he certainly was able to function," Gutekunst said, via Rob Demovsky of ESPN. "But as we looked at all the options and he did as well, the best option I think for him to get back the fastest and feel the best was to do this. He wanted to go out there yesterday to kind of see how it felt, and once we got through that, we made the decision." That's good news for the Packers, who have a tough slate to begin the season. Green Bay hosts Detroit in Week 1, and hosts the Commanders in Week 2 on Amazon Prime. The most encouraging part of this for the Packers is that Love's left non-throwing hand is involved. However, for a quarterback, the opposite hand is important, too. An injury to the non-throwing hand could impact Love's ability to receive the snap under center. The Packers believe that with Love undergoing the procedure, there will be no issues for Week 1, much less for Week 2. The Commanders were 12-5 last season and open the 2025 season against the New York Giants in Week 1. This will be Love's first meeting as a starting quarterback against Washington. It's also Jayden Daniels' first game against the Packers. This article originally appeared on Commanders Wire: Could Packers' injury impact their Week 2 vs. Commanders?
CNN
3 minutes ago
- CNN
NBA clears Boston Celtics' $6.1 billion sale to Bill Chisholm
A group headed by Bill Chisholm is set to take control of the Boston Celtics after the NBA Board of Governors unanimously approved the sale on Wednesday. The NBA wrote in a statement, 'The transaction is expected to close shortly.' The reported $6.1 billion valuation for the club makes it the second-largest sale price for a US sports franchise, behind the $10 billion valuation for the Los Angeles Lakers when Mark Walter purchased that team in June. Chisholm and his partners are buying at least 51 percent of the Celtics. The ownership stake will increase in 2028, according to the purchase contract, when Chisholm's group is scheduled to buy out the remaining minority shareholders at a $7.3 billion valuation. According to multiple media reports, Chisholm will take over as the Celtics' governor when the sale goes through. Outgoing owner Wyc Grousbeck is expected to serve as alternate governor and remain the CEO through 2028. Grousbeck will cede his role when he no longer has the required ownership stake of at least 15 percent. Chisholm, the co-founder and managing partner of the California-based private equity firm STG Partners, is a Massachusetts native and longtime Celtics fan. Grousbeck and the outgoing ownership group Boston Basketball Partners LLC purchased the Celtics for $360 million in 2002. During that group's tenure, the club won NBA titles in 2007-08 and 2023-24 – the latter representing Boston's league-record 18th championship.
Medscape
5 minutes ago
- Medscape
Calcium Deposition Can Increase Osteoarthritis Risk
Calcium crystal deposition may be a risk factor for knee osteoarthritis (OA), according to a new study. In an analysis including more than 6400 middle-aged to older adults, individuals with knee chondrocalcinosis were 75% more likely to develop knee OA than those without the condition at baseline. Because knee chondrocalcinosis and OA are often observed together, it is commonly considered a feature of the OA disease process, said Jean W. Liew, MD, an assistant professor of rheumatology at Boston University, Boston, and coauthor of the study. 'This study suggests that calcium crystal deposition is a cause of knee OA rather than just a consequence,' she told Medscape Medical News . The analysis included data from two independent cohorts: the Rotterdam Study (RS) and the Multicenter Osteoarthritis Study (MOST). RS enrolled individuals aged 55 years or older residing in Rotterdam, the Netherlands. MOST, which recruited participants from Birmingham, Alabama, and Iowa City, Iowa, enrolled adults aged 50-79 years with preexisting knee OA or at increased risk for OA due to overweight status, knee injury, or knee symptoms. Researchers examined the association between baseline knee chondrocalcinosis, measured via x-ray, and development of radiographic knee OA over time. Radiographic knee OA was defined as a Kellgren and Lawrence grade (KLG) ≥ 2 or if the individual had undergone knee replacement at follow-up. The analysis, published online on August 5, 2025, in Annals of the Rheumatic Diseases , included 3737 individuals from the RS cohort and 2750 individuals from the MOST cohort. At baseline in the RS cohort, 76.1% of participants had no signs of radiographic knee OA (KLG = 0), and 4.3% had knee chondrocalcinosis. For the MOST cohort, 68.5% had no signs of radiographic knee OA, and 5.0% had knee chondrocalcinosis at baseline. The analysis found that knee chondrocalcinosis increased the risk for incident radiographic knee OA after adjustment for age, sex, and BMI. The pooled odds ratio (OR) between both groups was 1.75 (95% CI, 1.25-2.27; P < .001). There were no cases of regression of chondrocalcinosis during follow-up, which suggests that chondrocalcinosis does not resolve over time, Liew and colleagues wrote. In a subgroup analysis including only individuals with KLG of 0 at baseline, the results were similar (OR = 1.77; 95% CI, 1.04-3.01; P = .035). More severe chondrocalcinosis was also associated with increased risk of developing knee OA. Commenting on the study for Medscape Medical News , Sara Tedeschi, MD, MPH, noted that these findings 'strongly suggest that [chondrocalcinosis] is a risk factor for the new development of osteoarthritis in people who don't currently have radiographic osteoarthritis.' Tedeschi is the head of crystal-induced arthritic diseases at Brigham and Women's Hospital in Boston. 'One of the unique features of this paper,' she said, 'is that they were able to look at knees that had chondrocalcinosis at baseline but no osteoarthritis at baseline and were able to follow them forward' with years of follow-up data. Treatment Options Liew now wants to explore whether treatments for inflammation related to calcium crystal deposition could also help prevent or delay progression of OA in this subset of patients. 'It's time to look at designing studies focused on this subgroup of people (with chondrocalcinosis on imaging) and testing whether treatments that work for crystal-associated arthritis like gout or calcium pyrophosphate deposition disease would also work for knee OA,' she said. 'Hints of such benefits have appeared in previous cardiovascular randomized controlled trials of colchicine, where patients receiving the drug had a lower risk of joint replacement as a secondary outcome,' noted Tedeschi. It's 'one interesting therapy to consider' for potential future trials, as are other anti-inflammatory medications like interleukin-1 inhibitors, she added.
